FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

Submitted by admin on July 29, 2021 - 10:57pm

Source:

Pharmaforum

News Tags:

Roche

faricimab

bispecific antibodies

diabetic macular edema

wet age-related macular degeneration

Headline:

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

snippet:

The FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, preparing for a market showdown with Bayer and Regeneron’s market-leading Eylea.

Search form

You are here

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict